title: [Immunomodulator treatment of multibacillary leprosy using extracts of microbial ribosomes].
abstract: Ribomunyl can in practice be profitably included in the range of immunostimulants, but it requires weekly injections and hence surveillance that will also enable any adverse reactions to be monitored. Its action and tolerance after polychemotherapy have still to be studied. On the basis of our experience, we feel that only isoprinosine, whose effectiveness and good tolerance we have demonstrated, can be used for self-treatment in a mass campaign.
authors: Association Franćaise des Fondations Raoul Follerau, Paris, France.
authors: P
authors: P
authors: Saint-André
authors: G
authors: G
authors: Baquillon
authors: M
authors: M
authors: David
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000942:Antigens, Bacterial / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007542:Inosine Pranobex / Q000627:therapeutic use; D015439:Leprosy, Borderline / Q000188:drug therapy / Q000628:therapy; D015440:Leprosy, Lepromatous / Q000188:drug therapy / Q000628:therapy*; D007978:Levamisole / Q000627:therapeutic use; D008297:Male
chemical_list: D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; C034206:Ribomunyl; D007978:Levamisole; D007542:Inosine Pranobex
vernacular_title: Traitement immunomodulant de la lèpre multibacillaire par extraits de ribosomes microbiens.